Ligand antagonists for treatment of breast cancer

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 38/27 (2006.01) A61P 35/00 (2006.01) C07K 14/61 (2006.01) C07K 14/705 (2006.01) C07K 14/72 (2006.01)

Patent

CA 2154163

We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described. Methods for inhibiting the growth of breast cancer cells are also described.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Ligand antagonists for treatment of breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ligand antagonists for treatment of breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ligand antagonists for treatment of breast cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1409312

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.